Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes
MB McGuckin, J Wang, R Ghanma, N Qin… - Journal of Controlled …, 2022 - Elsevier
The poor aqueous solubility of many approved drugs and most new chemical entities poses
a challenge to drug delivery scientists working in academic and industrial labs. Despite the …
a challenge to drug delivery scientists working in academic and industrial labs. Despite the …
Long-acting injectable antiretrovirals for HIV treatment and prevention
WR Spreen, DA Margolis… - Current Opinion in HIV …, 2013 - journals.lww.com
Investigational long-acting injectable nanoformulations of rilpivirine and GSK1265744 are
clinical-stage development candidates. Complementary pharmacologic properties of both …
clinical-stage development candidates. Complementary pharmacologic properties of both …
Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production
N Fintelman-Rodrigues, CQ Sacramento… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for
far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The …
far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The …
Long-acting HIV drugs for treatment and prevention
RM Gulick, C Flexner - Annual review of medicine, 2019 - annualreviews.org
Antiretroviral drugs have revolutionized the treatment and prevention of HIV infection;
however, adherence is critical for sustained efficacy. Current HIV treatment consists of three …
however, adherence is critical for sustained efficacy. Current HIV treatment consists of three …
Creation of a long-acting nanoformulated dolutegravir
Potent antiretroviral activities and a barrier to viral resistance characterize the human
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir …
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir …
Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs
In spite of introduction of combination antiretroviral therapy (cART) against human
immunodeficiency virus (HIV) infection; inaccessibility and poor adherence to oral cART …
immunodeficiency virus (HIV) infection; inaccessibility and poor adherence to oral cART …
Long-acting antiviral agents for HIV treatment
DA Margolis, M Boffito - Current Opinion in HIV and AIDS, 2015 - journals.lww.com
Phase II studies evaluating the coadministration of rilpivirine and cabotegravir
intramuscularly to HIV-infected individuals with an undetectable viral load are currently …
intramuscularly to HIV-infected individuals with an undetectable viral load are currently …
Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies
Human immunodeficiency virus (HIV) infection commonly results in a myriad of comorbid
conditions secondary to immune deficiency. Infection also affects broad organ system …
conditions secondary to immune deficiency. Infection also affects broad organ system …
Long-acting slow effective release antiretroviral therapy
Introduction: Advances in long-acting antiretroviral therapy (ART) can revolutionize current
HIV/AIDS treatments. We coined the term 'long-acting slow effective release ART'(LASER …
HIV/AIDS treatments. We coined the term 'long-acting slow effective release ART'(LASER …
Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV
DE Dow, JA Bartlett - Infectious diseases and therapy, 2014 - Springer
The integrase strand transfer inhibitors (INSTIs) are the newest antiretroviral class in the HIV
treatment armamentarium. Dolutegravir (DTG) is the only second-generation INSTI with FDA …
treatment armamentarium. Dolutegravir (DTG) is the only second-generation INSTI with FDA …